Parkinson’s indication for LCT
Thursday, 11 December, 2008
Auckland xenotransplantation company Living Cell Technologies reports that pre-clinical trials show its encapsulated porcine brain cells may be beneficial in Parkinson’s disease.
LCT is considering its NeurotrophinCell (NtCell) product in stroke, Alzheimer’s and Huntington’s, amongst others.
The company said studies showed the product – encapsulated brain choroid plexus cells – improved limb function in a Parkinson’s rat model.
The choroid plexus produces cerebrospinal fluid. The pig-derived cells were implanted to supply the nerve growth factor neurotrophins to repair diseased tissue.
The company, which is in human clinical trials in New Zealand and Russia for its encapsulated porcine islet cells for diabetes, has filed a patent for the new indication.
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
